Moberg Pharma AB (OSTO:MOB)
kr 10.21 -0.29 (-2.76%) Market Cap: 476.74 Mil Enterprise Value: 171.44 Mil PE Ratio: 0 PB Ratio: 0.53 GF Score: 46/100

Fifth Quarter 2020 Moberg Pharma AB (publ) Earnings Call Transcript

Nov 10, 2020 / 02:00PM GMT
Release Date Price: kr52.49 (+0.27%)
Operator

Hello, and welcome to the Moberg Pharma conference call. (Operator Instructions) Just to remind you, this conference call is being recorded.

Today, I'm pleased to present CEO, Anna Ljung. Please begin your meeting.

Anna Ljung;publ;CEO
Moberg Pharma AB

()-

Thank you, and hello. My name is Anna Ljung, and I'm the CEO of Moberg Pharma. I also have our VP of Finance, Mark Beveridge with me on this call today. I'm happy to present our interim report for the fifth quarter since we had a prolonged year, July to September 2020. You can find the report on our web page, and there you can also find a PowerPoint presentation that will be used as the basis for this telephone meeting.

So I will start on Page 3 in that presentation, with the brief introduction to Moberg Pharma. So we are a Swedish pharmaceutical company that base our products on drug delivery of known substances, which reduces time to market and development risk compared to traditional drug development. And our lead program is MOB-015 against onychomycosis,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot